 |
2 Diseases |  |
0 Trials |
|
0 Trials |  |
21 News |  |
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
New P1 trial: Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment (clinicaltrials.gov) - Jul 27, 2015
P1, N=31, Terminated, Sponsor: Cubist Pharmaceuticals Holdings LLC
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial primary completion date: The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Feb 5, 2015
P3, N=44, Terminated, Sponsor: Cubist Pharmaceuticals
Trial primary completion date: Mar 2015 --> Feb 2014
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial primary completion date: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Feb 5, 2015
P3, N=49, Terminated, Sponsor: Cubist Pharmaceuticals
Trial primary completion date: Mar 2015 --> Feb 2014 Trial primary completion date: Mar 2015 --> Feb 2014
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial primary completion date: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Feb 5, 2015
P3, N=61, Terminated, Sponsor: Cubist Pharmaceuticals
Trial primary completion date: Mar 2015 --> Feb 2014 Trial primary completion date: Mar 2015 --> Jan 2014
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial primary completion date: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Feb 5, 2015
P3, N=1407, Terminated, Sponsor: Cubist Pharmaceuticals
Trial primary completion date: Mar 2015 --> Jan 2014 Trial primary completion date: Dec 2014 --> Jun 2014
- | bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial termination: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Oct 24, 2014
P3, N=1407, Terminated, Sponsor: Cubist Pharmaceuticals
Trial primary completion date: Dec 2014 --> Jun 2014 Active, not recruiting --> Terminated; A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial termination: The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=44, Terminated, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Terminated; A review of blinded data indicates that the number of participant exposures needed to reach ICH standards has been met Active, not recruiting --> Terminated; Due to difficulties with enrollment, the study was terminated early.
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial termination: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=49, Terminated, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Terminated; Due to difficulties with enrollment, the study was terminated early. Active, not recruiting --> Terminated; Sponsor decision due to lack of enrollment.
- | bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial termination: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=61, Terminated, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Terminated; Sponsor decision due to lack of enrollment. Active, not recruiting --> Terminated; Sponsor decision due to lack of enrollment.
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Enrollment change: The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=44, Terminated, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Terminated; Sponsor decision due to lack of enrollment. N=600 --> 44
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Enrollment change: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=49, Terminated, Sponsor: Cubist Pharmaceuticals
N=600 --> 44 N=600 --> 49
- | bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Enrollment change: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=61, Terminated, Sponsor: Cubist Pharmaceuticals
N=600 --> 49 N=600 --> 61
- ||||| bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Enrollment closed: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Mar 2, 2014
P3, N=1400, Active, not recruiting, Sponsor: Cubist Pharmaceuticals
N=600 --> 61 Recruiting --> Active, not recruiting
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
New P3 trial: The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Jul 15, 2013
P3, N=44, Terminated, Sponsor: Cubist Pharmaceuticals
- bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
New P3 trial: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Jul 15, 2013
P3, N=49, Terminated, Sponsor: Cubist Pharmaceuticals
- || bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
New P3 trial: Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Jul 15, 2013
P3, N=61, Terminated, Sponsor: Cubist Pharmaceuticals
- |||||||||| bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
New P3 trial: Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - Sep 27, 2012
P3, N=1400, Active, not recruiting, Sponsor: Cubist Pharmaceuticals
- |||| bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial completion: Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain (clinicaltrials.gov) - Aug 15, 2011
P2, N=80, Completed, Sponsor: Cubist Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| bevenopran (CB-5945) / Eli Lilly, Merck (MSD)
Trial completion: Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain (clinicaltrials.gov) - Aug 15, 2011
P2, N=120, Completed, Sponsor: Cubist Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed